Moxifloxacin associated with faster clinical recovery than levofloxacin in CAP treatment
A prospective, double-blind, randomized, controlled trial comparing the effectiveness of levofloxacin and moxifloxacin in treating community-acquired pneumonia (CAP) among 394 hospitalized elderly patients (aged 65 years and older) demonstrated that moxifloxacin resulted in faster recovery than levofloxacin.
A prospective, double-blind, randomized, controlled trial comparing the effectiveness of levofloxacin and moxifloxacin in treating community-acquired pneumonia (CAP) among 394 hospitalized elderly patients (aged 65 years and older) demonstrated that moxifloxacin resulted in faster recovery than levofloxacin.
The Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE) study, published in the journal Clinical Infectious Diseases, also demonstrated that moxifloxacin was a more effective treatment for moderate and severe CAP in that age group.
"The CAPRIE study is very unique in that it was conducted only in patients 65 and older, such as the median age was 78," said Antonio Anzueto, MD, professor of medicine at the University of Texas Health Science Center and lead investigator.
Researchers measured patients' clinical response at a visit between the 5th and 21st days following the end of treament. Secondary end points measured patients' clinical response between the 3rd and 5th days of treatment and the bacteriologic response after the end of treatment.
For the primary end point, moxifloxacin cured 92.9% of the clinically valid patients while 87.9% of the levofloxacin group was cured (95% CI, –1.9 to 11.9; P=0.2). Between Days 3 and 5 of treatment, 97.9% of the moxifloxacin group was clinically recovered compared with 90% of the levofloxacin group (95% CI, 1.7–14.1; P=.01).
Moxifloxacin also was more efficacious in curing moderate (92.6%) and severe (94.7%) CAP than levofloxacin (88.6% and 84.6%, respectively, P=NS). Among patients aged 75 years and older, moxifloxacin cured 94.5% of patients compared with 90% of patients in the levofloxacin group (P=NS). Among those aged younger than 75 years, moxifloxacin cured 90% of patients compared with levofloxacin's 85% cure rate (P=NS).
SOURCE Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH; for the Community-Acquired Pneumonia Recovery in the Elderly Study Group. Community-acquired pneumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis. 2006;42:73–81.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
